Moderna Announces 2024 Financial Results and Future Projections

Moderna, Inc. reported its financial performance for the fourth quarter and fiscal year 2024, highlighting revenues of $1.0 billion for Q4 with a GAAP net loss of $1.1 billion. Full-year revenues totaled $3.2 billion, with a net loss of $3.6 billion. The company's focus on cost reduction resulted in a 27% decrease in expenses compared to 2023. For 2025, Moderna anticipates revenues between $1.5 and $2.5 billion and a cash balance of approximately $6 billion.

The company submitted three investigational mRNA products for approval, including a next-generation COVID vaccine, an RSV vaccine for high-risk adults, and a combined flu/COVID vaccine. Recent product approvals include Spikevax® and mRESVIA®. Moderna continues to aim for up to 10 product approvals by 2027, supported by advancing pipelines and strategic collaborations.